Navigation Links
Glutamate: Too much of a good thing in schizophrenia?
Date:10/27/2008

Philadelphia, PA, October 27, 2008 Is schizophrenia a disorder of glutamate hyperactivity or hypoactivity? While the predominant hypothesis for many years was that schizophrenia was a glutamate deficit disorder, there is growing evidence of glutamate hyperactivity as well. The study by Karlsson et al., appearing in the November 1st issue of Biological Psychiatry, reinforces this point with new data about the impact of deleting the gene for the glutamate transporter EAAT1. EAAT1, implicated in schizophrenia, plays a critical role in inactivating glutamate by removing it from the synaptic and extracellular spaces. The authors demonstrate that these "knockout" animals show increased responses to the NMDA glutamate receptor antagonist, MK-801. This drug causes the release of more glutamate into the synapse in the frontal cortex. This effect of MK-801 is reduced by a group II metabotropic glutamate receptor agonist, which reduces glutamate release. Dr. Andrew Holmes, corresponding author, further discusses their findings, "Our study adds a new twist to [glutamate] research by showing that genetically disrupting a major regulator of glutamate's ability to communicate between nerve cells produces certain 'schizophrenia-like' features in mice and, moreover, that these abnormalities can be corrected by a highly promising new class of glutamate-targeting antipsychotic treatments." In fact, this class of drugs has already shown some preliminary efficacy in its ability to treat individuals suffering from schizophrenia.

John H. Krystal, M.D., Editor of Biological Psychiatry and affiliated with both Yale University School of Medicine and the VA Connecticut Healthcare System, comments: "The NMDA receptor antagonist model and the EAAT1 knockout animal push us to take a fresh look at the obstacles to treating cognitive impairments associated with schizophrenia, in other words, optimizing their cortical network function. This new look can lead us to drugs that would have been completely surprising as recently as 10 years ago, such as the group II metabotropic glutamate receptor agonists."

Dr. Holmes does note that further research is warranted, stating, "What is now needed is more research to get a better handle on how disrupting this gene affects the brain's neural wiring and molecular signaling pathways to produce the symptoms of schizophrenia." This finding could ultimately help scientists develop new or improved treatments for this schizophrenia.


'/>"/>

Contact: Jayne Dawkins
ja.dawkins@elsevier.com
215-239-3674
Elsevier
Source:Eurekalert

Related medicine news :

1. MSAs Next-Generation Breathing Apparatus for Firefighters First to Receive Full NFPA Approval
2. Wanting a bite of everything: Hungry people crave more variety
3. Non-Stick Gum Something to Chew On
4. VIDEO from Medialink and Siemens: The Next Generation Allergy Test - Nothing to Sneeze At
5. Something Wicked! This Way Comes: Elvira Hosts Halloween Fashion Show and Fundraiser Benefiting AIDS Healthcare Foundation
6. The Ultimate Stress Reliever, SpaCapsule(R), the Capsule that Takes You on a Rejuvenating Journey to the Spa, Retains TransMedia Group for Soothing PR
7. The USDA E. coli Loophole in Ground Beef: Much Ado About Nothing
8. Childhood sleep-disordered breathing disproportionately affects obese and African-Americans
9. Its not just a kid thing: Fluoridated tap water benefits older adults even more
10. Patients wonder, Could this be something serious?
11. Honey Beats Meds at Soothing Kids Cough
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Appleton, WI (PRWEB) , ... March 28, 2017 ... ... how self-funded health plans work, the Self-Funding Success website has recently developed and ... about Self-Funded Health Plans ” was created based on common inquiries the site’s ...
(Date:3/28/2017)... CA (PRWEB) , ... March 28, 2017 , ... ... Carson Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer the recently ... balloon procedure, and this procedure adds to SkyLex Advanced Surgical’s already comprehensive ...
(Date:3/28/2017)... ... March 28, 2017 , ... Oily skin is a common and unwelcomed occurrence in people of ... a lot to offer to the discussion of dealing with excess skin oil. “Oily skin ... many home remedies that can help remove the oily shine while keeping the skin fresh ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep apnea ... with or without a referral. Sleep apnea is often left untreated because patients are ... headaches and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep ...
(Date:3/27/2017)... Philadelphia PA and London UK (PRWEB) , ... ... ... have the speed, agility and ability to gain site attention and engagement over ... DrugDev educational webinar will discuss how partnering with the ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... SAN DIEGO and VANCOUVER, British Columbia, March 27, ... SPHS ) (the "Company" or "Sophiris"), a clinical ... treatment of patients with urological diseases, today reported ... and key corporate highlights. Key ... in Clinical Development for Localized Prostate Cancer. During ...
(Date:3/27/2017)... , March 27, 2017 /PRNewswire/ - INVICTUS MD ... IVITF; FRA: 8IS) Invictus MD is pleased to announce ... shares for trading on the TSX Venture Exchange.  ... TSXV follows a year of significant achievements for Invictus-MD. ... successful test crops at AB Laboratories Inc. ("AB Labs"), ...
(Date:3/27/2017)... , March 27, 2017 The ... reach USD 16.0 billion by 2025, according to a ... prevalence of chronic diseases is anticipated to be responsible ... which thereby widens the scope for growth during the ... bariatric population, which is highly susceptible to chronic diseases, ...
Breaking Medicine Technology: